等待开盘 09-26 09:30:00 美东时间
-0.060
-0.51%
今日重点评级关注:BTIG:维持Kazia Therapeutics"买入"评级,目标价从34美元升至40美元;摩根大通:维持Annexon"超配"评级,目标价从10美元升至14美元
09-02 14:07
Wells Fargo analyst Blaine Heck maintains Hudson Pacific Properties (NYSE:HPP) with a Overweight and raises the price target from $14 to $17.
09-01 23:22
今日重点评级关注:康托·菲茨杰拉德:维持EyePoint"超配"评级,目标价从47美元升至55美元;伯恩斯坦:维持Figure Technology"跑赢大市"评级,目标价从67美元升至70美元
08-07 13:41
Hudson Pacific Properties (NYSE:HPP) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.26 by 34.62 percent. This is a 29.63 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $188.298 ...
08-05 21:01
Hudson Pacific Properties (NYSE:HPP) raises FY2026 FFO guidance from $1.10-$1.18 to $1.12-$1.20 vs $1.06 analyst estimate..
08-05 21:00
今日重点评级关注:HC Wainwright & Co.:维持IREN"买入"评级,目标价从85美元升至90美元;BTIG:维持FTAI Aviation"买入"评级,目标价从340美元升至400美元
07-23 13:42
今日重点评级关注:HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从50美元升至69美元;高盛:维持Taysha Gene Therapies"买入"评级,目标价从11美元升至13美元
07-22 11:35
Mizuho analyst Vikram Malhotra maintains Hudson Pacific Properties (NYSE:HPP) with a Neutral and raises the price target from $15 to $17.
07-21 20:58
今日重点评级关注:摩根大通:上调Camp4 Therapeutics评级至"超配",目标价从5美元升至9美元;Canaccord Genuity:维持Rhythm制药"买入"评级,目标价从143美元升至151美元
06-17 11:32
今日重点评级关注:HC Wainwright & Co.:维持Elicio Therapeutics"买入"评级,目标价从17美元升至23美元;Leerink Partners:维持SAB Biotherapeutics"跑赢大市"评级,目标价从7美元升至12美元
06-16 11:34